Funding boost for cystic fibrosis research

WA-based cystic fibrosis research projects will receive $2 million in funding to support their ground-breaking work throughout 2025.


Across the State hundreds of people are affected by cystic fibrosis, a life-limiting condition that has a high burden on individuals, their families, loved ones and carers.

The State Government committed $1 million in co-funding to bolster cystic fibrosis research projects across WA, matching an investment by Cystic Fibrosis WA and Conquer Cystic Fibrosis.

The funding for the WA Cystic Fibrosis Research Collaborative 2025 program will support WA-based research projects that are committed to exploring alternate therapies and treatment options to improve the lives of people with cystic fibrosis, a condition impacting over 430 people in WA.

Mitch Messer, 2024 West Australian of the Year, Community, for his work in advocacy for cystic fibrosis care, said the funding collaborative was encouraging.

“Cystic fibrosis has a huge impact on families and while treatments have come a long way, there’s still work to do,” he said.

“This investment will help speed progress so that people living with cystic fibrosis can have a future where they can plan and live their lives without the constant shadow of cystic fibrosis hanging over their heads and we are deeply grateful for this critical support.”

Mr Messer was diagnosed with cystic fibrosis as a baby and his parents helped establish Cystic Fibrosis WA.

Chief executive of Cystic Fibrosis WA Lisa Bayakly said this was a huge step forward for those impacted by the condition.

“The program will boost WA’s excellent cystic fibrosis research community, with outcomes benefiting Western Australians and individuals nationally and globally,” she said.

“Research is vital, not only to improve life expectancy and quality of life for all people with cystic fibrosis but also to provide effective treatment options for those who currently have none.

“This funding will drive innovative solutions to tackle critical issues like antimicrobial resistance, which poses a significant risk to both the cystic fibrosis community and the broader population.

“It also allows us to address the many clinical aspects of cystic fibrosis beyond respiratory health, ensuring more comprehensive care for individuals living with this condition.”